X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES AJANTA PHARMA ALKEM LABORATORIES/
AJANTA PHARMA
 
P/E (TTM) x - 20.4 - View Chart
P/BV x 7.1 4.8 147.2% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALKEM LABORATORIES   AJANTA PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
AJANTA PHARMA
Mar-18
ALKEM LABORATORIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,818 87.4%   
Low Rs1,2321,106 111.4%   
Sales per share (Unadj.) Rs417.5239.5 174.3%  
Earnings per share (Unadj.) Rs56.352.8 106.6%  
Cash flow per share (Unadj.) Rs64.759.5 108.7%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9230.0 127.4%  
Shares outstanding (eoy) m119.5788.77 134.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.46.1 55.3%   
Avg P/E ratio x25.127.7 90.5%  
P/CF ratio (eoy) x21.824.6 88.7%  
Price / Book Value ratio x4.86.4 75.7%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,653129,782 130.0%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m9,1713,765 243.6%   
Avg. sales/employee Rs ThNM3,128.4-  
Avg. wages/employee Rs ThNM554.0-  
Avg. net profit/employee Rs ThNM689.7-  
INCOME DATA
Net Sales Rs m49,91521,258 234.8%  
Other income Rs m1,645242 680.9%   
Total revenues Rs m51,56121,499 239.8%   
Gross profit Rs m8,4826,584 128.8%  
Depreciation Rs m1,006596 168.8%   
Interest Rs m6714 16,356.1%   
Profit before tax Rs m8,4516,226 135.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,539 104.3%   
Profit after tax Rs m6,7314,686 143.6%  
Gross profit margin %17.031.0 54.9%  
Effective tax rate %19.024.7 76.9%   
Net profit margin %13.522.0 61.2%  
BALANCE SHEET DATA
Current assets Rs m27,06212,236 221.2%   
Current liabilities Rs m15,3243,461 442.8%   
Net working cap to sales %23.541.3 57.0%  
Current ratio x1.83.5 49.9%  
Inventory Days Days6760 110.5%  
Debtors Days Days4184 48.9%  
Net fixed assets Rs m12,61011,140 113.2%   
Share capital Rs m239177 135.2%   
"Free" reserves Rs m34,49020,237 170.4%   
Net worth Rs m35,02720,414 171.6%   
Long term debt Rs m1,21210 11,996.0%   
Total assets Rs m54,38724,486 222.1%  
Interest coverage x13.61,519.4 0.9%   
Debt to equity ratio x00 6,991.4%  
Sales to assets ratio x0.90.9 105.7%   
Return on assets %13.619.2 71.0%  
Return on equity %19.223.0 83.7%  
Return on capital %24.930.5 81.5%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56311,667 56.3%   
Fx outflow Rs m3,0121,616 186.4%   
Net fx Rs m3,55210,052 35.3%   
CASH FLOW
From Operations Rs m7,2592,854 254.3%  
From Investments Rs m1,864-2,604 -71.6%  
From Financial Activity Rs m-9,273-2 463,635.0%  
Net Cashflow Rs m-150248 -60.5%  

Share Holding

Indian Promoters % 66.9 73.8 90.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 1.6 2,135.5%  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 17.0 -  
Shareholders   68,381 20,968 326.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 17.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, AJANTA PHARMA has posted a net profit of Rs 945 m (down 17.1% YoY). Sales on the other hand came in at Rs 5 bn (up 11.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 26, 2018 02:35 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS